NYSE$CLX
Clorox Co · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Reported better-than-expected results, fully restored overall market share, and updated outlook.
Clorox reported a 27% increase in net sales to $1.76 billion, driven by higher volume due to lapping the cyberattack. Diluted EPS increased by 371% to $0.80, and adjusted EPS increased by 280% to $1.86. The company has raised its gross margin and EPS outlook for the year.
- Net sales increased by 27% to $1.76 billion, driven by higher volume reflecting the lapping of the cyberattack.
- Gross margin increased by 740 basis points to 45.8%, primarily due to higher volume and cost savings.
- Diluted EPS increased by 371% to $0.80, driven by strong operational performance and lapping of the cyberattack.
- Adjusted EPS increased by 280% to $1.86, primarily due to higher net sales and cost savings.
Headline financials
Revenue & EPS history
Clorox · Revenue · Quarterly
$1.76B
Revenue by segment
Clorox · $824M total across 3 segments · Q1 2024
- Household$325M-23.2%39.4%
- International$270M-5.3%32.8%
- Lifestyle$229M-28.4%27.8%
Forward guidance
The company is updating its fiscal year 2025 outlook. Gross margin is now expected to be up about 100 to 150 basis points. Fiscal year diluted EPS is now expected to be between $5.17 and $5.42. Adjusted EPS is now expected to be between $6.65 and $6.90.
Tailwinds
- Gross margin is now expected to be up about 100 to 150 basis points, primarily due to the benefits of holistic margin management efforts.
- Fiscal year diluted EPS is now expected to be between $5.17 and $5.42, a year-over-year increase of 130% to 141%, respectively.
- Adjusted EPS is now expected to be between $6.65 and $6.90, a year-over-year increase of 8% to 12%, respectively.
- Net sales are still expected to be flat to down 2%.
- Organic sales are still expected to be up 3% to up 5%.
Headwinds
- Gross margin increase is partially offset by cost inflation and higher trade promotion spending.
- Net sales are expected to be flat to down 2%.
- Organic sales exclude about 2 points of negative impact from the divestiture of the company's business in Argentina.
- Organic sales exclude about 3 points of negative impact from the divestiture of the Better Health VMS business.
- Selling and administrative expenses continue to be expected to be between 15% to 16% of net sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.0%
Avg return
30 days after
55%
39 / 71 earnings
Positive
+9.5%
Q4 2023
Best reaction
-15.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.5% | -6.7% | -6.6% | |
| Q2 2026 | +4.6% | +4.0% | -0.3% | |
| Q1 2026 | +1.1% | -1.6% | -3.7% | |
| Q3 2025 | -2.4% | -2.6% | -8.0% | |
| Q2 2025 | -7.2% | -7.1% | -7.1% | |
| Q1 2025 | +1.1% | +3.6% | +6.6% | |
| Q4 2024 | +9.2% | +8.6% | +20.0% | |
| Q3 2024 | -6.2% | -7.2% | -13.4% | |
| Q2 2024 | +7.6% | +6.6% | +4.7% | |
| Q1 2024 | +4.5% | +9.6% | +22.2% | |
| Q4 2023 | +9.5% | +7.9% | +2.3% | |
| Q3 2023 | +5.1% | +1.5% | -5.1% | |
| Q2 2023 | +7.2% | +5.0% | +7.9% | |
| Q1 2023 | -5.7% | -3.7% | +2.6% | |
| Q4 2022 | -4.2% | +0.5% | -0.7% | |
| Q3 2022 | +2.9% | +7.3% | -1.9% | |
| Q2 2022 | -15.3% | -14.2% | -13.3% | |
| Q1 2022 | +1.5% | +0.2% | +1.7% | |
| Q4 2021 | -8.6% | -10.3% | -6.2% | |
| Q3 2021 | -2.9% | -1.0% | -5.0% | |
| Q2 2021 | -6.5% | -8.4% | -9.9% | |
| Q1 2021 | +2.4% | +5.2% | -2.7% | |
| Q4 2020 | +0.5% | +0.4% | -5.4% | |
| Q3 2020 | +6.9% | +7.2% | +10.6% | |
| Q2 2020 | +6.1% | +6.7% | +12.8% | |
| Q1 2020 | -2.5% | -2.0% | -1.7% | |
| Q4 2019 | -3.5% | -5.1% | -2.7% | |
| Q3 2019 | -6.9% | -7.2% | -6.8% | |
| Q2 2019 | +1.9% | +3.9% | +4.7% | |
| Q1 2019 | +0.6% | +2.7% | +8.4% | |
| Q4 2018 | +6.6% | +5.5% | +8.1% | |
| Q3 2018 | +1.4% | +3.4% | +3.1% | |
| Q2 2018 | -9.5% | -8.9% | -6.7% | |
| Q1 2018 | +2.2% | +0.9% | +10.4% | |
| Q4 2017 | +1.9% | +2.0% | +4.6% | |
| Q3 2017 | +1.7% | +1.4% | +5.0% | |
| Q2 2017 | +2.9% | +5.7% | +13.9% | |
| Q1 2017 | -4.0% | -4.4% | -4.6% | |
| Q4 2016 | +2.8% | +1.4% | +1.3% | |
| Q3 2016 | +1.8% | — | — | |
| Q2 2016 | -5.1% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | +4.4% | — | — | |
| Q3 2015 | +0.4% | — | — | |
| Q2 2015 | +0.3% | — | — | |
| Q1 2015 | +1.2% | — | — | |
| Q4 2014 | -0.6% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | -2.1% | — | — | |
| Q1 2014 | -0.6% | — | — | |
| Q4 2013 | -0.7% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | -0.6% | — | — | |
| Q3 2012 | -4.3% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | -2.9% | — | — | |
| Q4 2011 | +4.1% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2011 | +1.3% | — | — | |
| Q1 2011 | -2.2% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q4 2008 | +0.4% | — | — | |
| Q3 2010 | -1.5% | — | — | |
| Q3 2009 | -1.5% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q2 2009 | -0.1% | — | — | |
| Q1 2009 | -0.9% | — | — | |
| Q4 2009 | -0.9% | — | — | |
| Q1 2010 | -0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro